Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Genmab    GEN   DK0010272202

GENMAB

(GEN)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
05/15/2019 05/16/2019 05/20/2019 05/21/2019 05/22/2019 Date
1107.5(c) 1150.5(c) 1154(c) 1198.5(c) 1203(c) Last
92 954 182 500 158 421 204 595 174 320 Volume
-0.67% +3.88% +0.30% +3.86% +0.38% Change
More quotes
Financials (DKK)
Sales 2019 4 656 M
EBIT 2019 2 122 M
Net income 2019 1 758 M
Finance 2019 6 965 M
Yield 2019 -
Sales 2020 5 580 M
EBIT 2020 2 640 M
Net income 2020 2 064 M
Finance 2020 9 539 M
Yield 2020 -
P/E ratio 2019 39,31
P/E ratio 2020 33,53
EV / Sales2019 13,8x
EV / Sales2020 11,0x
Capitalization 71 179 M
More Financials
Company
Genmab specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (57.6%); - income from research and development (22.7%); - other... 
Sector
Biotechnology & Medical Research
Calendar
06/01 | 09:00amPresentation
More about the company
Surperformance© ratings of Genmab
Trading Rating : Investor Rating :
More Ratings
Latest news on GENMAB
05/16GENMAB A/S : has published its Articles of Association
AQ
05/16GENMAB : Announces Data to be Presented at 24th EHA Annual Congress
AQ
05/15GENMAB : Capital Increase in Genmab as a Result of Employee Warrant Exercise
AQ
05/14GENMAB : Capital Increase in Genmab as a Result of Employee Warrant Exercise
AQ
05/08Genmab Announces Financial Results for the First Quarter of 2019
GL
05/08GLOBAL MARKETS LIVE : Siemens, Airbus, Nestlé, Tesla…
05/03GENMAB A/S : quaterly earnings release
04/17GENMAB : Announces Data to be Presented at 2019 ASCO Annual Meeting
AQ
04/17GENMAB : Announces Net Sales of DARZALEX for First Quarter of 2019
AQ
04/16Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 20..
GL
More news
Analyst Recommendations on GENMAB
More recommendations
Stock Trading Strategies
GENMAB - 02/07
A good level to buy
BUY
More Stock Trading Analysis
Sector news : Bio Therapeutic Drugs
05/21Global chemical firms urged to source responsibly after lethal China blast - ..
RE
05/15GILEAD SCIENCES : Novartis gets approval to sell Kymriah in Japan for $306,000
RE
05/13REGENERON PHARMACEUTICALS : Says FDA Approves Eylea Injection for All Diabetic R..
DJ
05/10PATRICK THOMAS : Biotech Industry Woos Talent With Top Pay -- WSJ
DJ
05/09PATRICK THOMAS : Biotech Is Place to Be for Top Salaries
DJ
More sector news : Bio Therapeutic Drugs
Chart GENMAB
Duration : Period :
Genmab Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GENMAB
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 1 341  DKK
Spread / Average Target 16%
EPS Revisions
Managers
NameTitle
Jan G. J. van de Winkel President & Chief Executive Officer
Mats Gunnar Pettersson Chairman
Michael K. Bauer SVP, Head-Operations, Research & Development
David Andrew Eatwell Chief Financial Officer & Executive Vice President
Anders Gersel Pedersen Deputy Chairman
Sector and Competitors
1st jan.Capitalization (M$)
GENMAB12.27%10 632
GILEAD SCIENCES6.35%83 745
VERTEX PHARMACEUTICALS2.06%42 447
REGENERON PHARMACEUTICALS-17.01%32 595
SAREPTA THERAPEUTICS INC11.05%8 718
BEIGENE LTD--.--%7 824